Last reviewed · How we verify
CD-008-0045
CD-008-0045 is a small molecule that targets the molecular target.
CD-008-0045 is a small molecule that targets the molecular target. Used for unknown.
At a glance
| Generic name | CD-008-0045 |
|---|---|
| Sponsor | ChemRar Research and Development Institute, LLC |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | unknown |
| Phase | Phase 3 |
Mechanism of action
CD-008-0045 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- unknown
Common side effects
- unknown
Key clinical trials
- A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder (PHASE3)
- А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD-008-0045 CI brief — competitive landscape report
- CD-008-0045 updates RSS · CI watch RSS
- ChemRar Research and Development Institute, LLC portfolio CI